A Phase 1, Open-Label Study to Characterize the Pharmacokinetics and Safety of a Single Oral Dose of GBT440 in Subjects With Hepatic Impairment
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Voxelotor (Primary)
- Indications Liver disorders
- Focus Pharmacokinetics
- Sponsors Global Blood Therapeutics
- 20 Feb 2018 Planned End Date changed from 1 Nov 2017 to 8 Mar 2018.
- 20 Feb 2018 Planned primary completion date changed from 1 Nov 2017 to 21 Feb 2018.
- 20 Feb 2018 Status changed from recruiting to active, no longer recruiting.